Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christian Uprimny

Showing results (21-30 of 58) with videos related to

Pageof 6
Sort By:
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 20, 2009
68Ga-DOTA-Tyr3-octreotide PET for assessing response to somatostatin-receptor-mediated radionuclide therapyMichael Gabriel, Andreas Oberauer, Georg Dobrozemsky, et al.
European Journal of Nuclear Medicine and Molecular Imaging|May 14, 2016
Current knowledge on the sensitivity of the (68)Ga-somatostatin receptor positron emission tomography and the SUVmax reference range for management of pancreatic neuroendocrine tumoursIrene Virgolini, Michael Gabriel, Alexander Kroiss, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 21, 2009
Bone metastases in patients with neuroendocrine tumor: 68Ga-DOTA-Tyr3-octreotide PET in comparison to CT and bone scintigraphyDaniel Putzer, Michael Gabriel, Benjamin Henninger, et al.
Clinical Nuclear Medicine|May 23, 2012
First experience with proteasome inhibitor treatment of radioiodine nonavid thyroid cancer using bortezomibDaniel Putzer, Micheal Gabriel, Alexander Kroiss, et al.
World Journal of Urology|May 8, 2019
Organ-sparing surgery of penile cancer: higher rate of local recurrence yet no impact on overall survivalAndrea Katharina Lindner, Gert Schachtner, Eberhard Steiner, et al.
European Journal of Nuclear Medicine and Molecular Imaging|February 1, 2011
Functional imaging in phaeochromocytoma and neuroblastoma with 68Ga-DOTA-Tyr 3-octreotide positron emission tomography and 123I-metaiodobenzylguanidineAlexander Kroiss, Daniel Putzer, Christian Uprimny, et al.
European Journal of Nuclear Medicine and Molecular Imaging|February 29, 2016
Direct comparison of (68)Ga-DOTA-TOC and (18)F-FDG PET/CT in the follow-up of patients with neuroendocrine tumour treated with the first full peptide receptor radionuclide therapy cycleBernhard Nilica, Dietmar Waitz, Vlado Stevanovic, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 3, 2007
68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CTMichael Gabriel, Clemens Decristoforo, Dorota Kendler, et al.
European Journal of Nuclear Medicine and Molecular Imaging|January 14, 2017
The <sup>68</sup>Ga/<sup>177</sup>Lu theragnostic concept in PSMA targeting of castration-resistant prostate cancer: correlation of SUV<sub>max</sub> values and absorbed dose estimatesLorenza Scarpa, Sabine Buxbaum, Dorota Kendler, et al.
Cancers|February 25, 2023
Correction: von Eyben et al. A Risk Model for Patients with PSA-Only Recurrence (Biochemical Recurrence) Based on PSA and PSMA PET/CT: An Individual Patient Data Meta-Analysis. <i>Cancers</i> 2022, <i>14</i>, 5461Rie von Eyben, Daniel S Kapp, Manuela Andrea Hoffmann, et al.
Pageof 6

Showing results (21-30 of 58) with videos related to

Sort By:
Pageof 6
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 20, 2009
68Ga-DOTA-Tyr3-octreotide PET for assessing response to somatostatin-receptor-mediated radionuclide therapyMichael Gabriel, Andreas Oberauer, Georg Dobrozemsky, et al.
European Journal of Nuclear Medicine and Molecular Imaging|May 14, 2016
Current knowledge on the sensitivity of the (68)Ga-somatostatin receptor positron emission tomography and the SUVmax reference range for management of pancreatic neuroendocrine tumoursIrene Virgolini, Michael Gabriel, Alexander Kroiss, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 21, 2009
Bone metastases in patients with neuroendocrine tumor: 68Ga-DOTA-Tyr3-octreotide PET in comparison to CT and bone scintigraphyDaniel Putzer, Michael Gabriel, Benjamin Henninger, et al.
Clinical Nuclear Medicine|May 23, 2012
First experience with proteasome inhibitor treatment of radioiodine nonavid thyroid cancer using bortezomibDaniel Putzer, Micheal Gabriel, Alexander Kroiss, et al.
World Journal of Urology|May 8, 2019
Organ-sparing surgery of penile cancer: higher rate of local recurrence yet no impact on overall survivalAndrea Katharina Lindner, Gert Schachtner, Eberhard Steiner, et al.
European Journal of Nuclear Medicine and Molecular Imaging|February 1, 2011
Functional imaging in phaeochromocytoma and neuroblastoma with 68Ga-DOTA-Tyr 3-octreotide positron emission tomography and 123I-metaiodobenzylguanidineAlexander Kroiss, Daniel Putzer, Christian Uprimny, et al.
European Journal of Nuclear Medicine and Molecular Imaging|February 29, 2016
Direct comparison of (68)Ga-DOTA-TOC and (18)F-FDG PET/CT in the follow-up of patients with neuroendocrine tumour treated with the first full peptide receptor radionuclide therapy cycleBernhard Nilica, Dietmar Waitz, Vlado Stevanovic, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 3, 2007
68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CTMichael Gabriel, Clemens Decristoforo, Dorota Kendler, et al.
European Journal of Nuclear Medicine and Molecular Imaging|January 14, 2017
The <sup>68</sup>Ga/<sup>177</sup>Lu theragnostic concept in PSMA targeting of castration-resistant prostate cancer: correlation of SUV<sub>max</sub> values and absorbed dose estimatesLorenza Scarpa, Sabine Buxbaum, Dorota Kendler, et al.
Cancers|February 25, 2023
Correction: von Eyben et al. A Risk Model for Patients with PSA-Only Recurrence (Biochemical Recurrence) Based on PSA and PSMA PET/CT: An Individual Patient Data Meta-Analysis. <i>Cancers</i> 2022, <i>14</i>, 5461Rie von Eyben, Daniel S Kapp, Manuela Andrea Hoffmann, et al.
Pageof 6